Actively Recruiting
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
Led by First Affiliated Hospital of Fujian Medical University · Updated on 2024-12-16
5
Participants Needed
1
Research Sites
79 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.
CONDITIONS
Official Title
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Various solid tumors with available histopathological findings
- Signed informed consent
You will not qualify if you...
- Pregnant or lactational women
- Severe hepatic and renal insufficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005
Actively Recruiting
Research Team
W
Weibing Miao, MD
CONTACT
R
Rong Lin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here